http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2751007-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_79ae6dd5bafbd2dd69035367385d754c |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-689 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G09B23-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-74 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G09B23-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate | 2020-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b10a9428dce35fe4bcdd833b33720489 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0fe5ef52ce2e3a41162d22a668825a07 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f27a827111658f49beddd7cb6c0569dc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_edb64a4d76904da76af70cebf29fa96d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_47ffd2828f973538bb26fc3865d36213 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_99ea99418db049ed06c6f81a6bc7c902 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d77b8c765f6d7a8a7961c5e5004e44c4 |
| publicationDate | 2021-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2751007-C1 |
| titleOfInvention | Method for predicting the development of extraretinal vasoproliferation in experimental retinopathy of prematurity (rop) |
| abstract | FIELD: medicine. n SUBSTANCE: invention relates to medicine, namely to ophthalmology, and can be used to predict the development of extraretinal vasoproliferation in experimental retinopathy of prematurity (ROP). On the 14th day of life in rat pups with a PH model, the content of L-deoxyphenylalanine (L-DOPA) is determined in the blood plasma. When its level is equal to or below 0.31 ng/ml, the development of ROP is predicted. n EFFECT: invention provides the possibility of predicting the risk of developing extraretinal vasoproliferation in experimental retinopathy of prematurity in a rat model of the disease in order to substantiate the possibility of laboratory screening of ROP in the clinic by determining the level of L-DOPA in the blood plasma of rat pups with ROP model on the 14th day of the experiment. n 1 cl, 1 tbl, 4 ex |
| priorityDate | 2020-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 127.